Skip to main content
John Byrd, MD, Hematology, Cincinnati, OH, University of Cincinnati Medical Center

JohnC.ByrdMD

Hematology • Cincinnati, OH

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Clinical Pharmacology

Chair and Professor, Department of Internal Medicine

Join to view full profile

Dr. Byrd is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Byrd's full profile

Already have an account?

  • Office

    231 Albert Sabin Way, ML 0551, Room 6065 Cincinnati OH 45267-0551
    Cincinnati, OH 45267
    Phone+1 513-558-0858
  • Is this information wrong?

Summary

  • I am currently Chair, Department of Internal Medicine at the University of Cincinnati and also a physician scientist who has done translational and clinical drug development for two decades. Closest to me professional being is performing as an exceptional, empathetic board certified hematologist in care of patients with blood cancers. My laboratory and clinical research has directly resulted in 7 drugs getting FDA approval. This experience bridges close interaction with industry as a consultant to develop and implement a successful development plan (Calistoga, Idelalisib) to performing pre-clinical and clinical work in my University role focused on a single class of drugs that transformed the care of CLL (Ibrutinib, Acalabrutinib) and other B-cell malignancies. My role in the current Leukemia and Lymphoma Society Beat AML Study as Principal and Chief Medical Officer has offered an even larger extension of this by planning, implementing, and running a multi-center umbrella study in AML that brings together academic clinical investigators, diagnostic companies, pharmaceutical companies, clinical research organizations and the FDA to effectively move new therapies forward to the clinic.

Education & Training

  • National Capital Consortium
    National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1994 - 1997
  • National Capital Consortium (Walter Reed)
    National Capital Consortium (Walter Reed)Residency, Internal Medicine, 1991 - 1994
  • University of Arkansas For Medical Sciences College of Medicine
    University of Arkansas For Medical Sciences College of MedicineClass of 1991
  • Hendrix College
    Hendrix CollegeB.A., Chemistry, With distinction, 1987

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2001 - 2025
  • VA State Medical License
    VA State Medical License 1993 - 2020

Awards, Honors, & Recognition

  • Return of the Child Award Leukemia and Lymphoma Society, 2017
  • Fellow American College of Physicians, 2017
  • Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research AACR, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Non-Hodgkin’s lymphomas  
    Zelenetz AD, Abramson JS, Advani RH, Andreadis B, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz..., J Natl Compr Canc Netw, 1/1/2011
  • Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors  
    Lu Q, Yang YT, Chen CS, Davis M, Byrd JC, Etherton MR, Umar A, Chen CS, J Med Chemistry, 1/15/2004
  • Enhanced pneumocystis carinii activity of new primaquine analogues  
    Goodwin TE, Boylan CJ, Current WL, Byrd JC, Edwards CB, Fuller DA, Green JL, Larocca CD, Raney KD, Ross AS, Tucker WA, Bioorg Med Chem Lett, 1/2/2000
  • Join now to see all

Press Mentions

  • New Drug May Be Best Treatment for Leukemia Yet
    New Drug May Be Best Treatment for Leukemia YetOctober 25th, 2022
  • Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance Its Clinical Pipeline
    Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance Its Clinical PipelineApril 1st, 2021
  • What Patients with CLL/SLL Should Know About the FDA
    What Patients with CLL/SLL Should Know About the FDANovember 27th, 2019
  • Join now to see all

Grant Support

  • Lenalidomide As An Immune Modulating Agent For Chronic Lymphocytic LeukemiaNational Cancer Institute2009–2011
  • Experimental Therapeutics Of LeukemiaNational Cancer Institute2009–2011
  • Administration And OperationsNational Cancer Institute2009–2011
  • Translational Training Grant In Experimental TherapeuticsNational Cancer Institute2008–2011
  • Innate Immune Therapies In B Cell MalignanciesNational Cancer Institute2007–2011
  • 2010 Clinical Research Training Institute Summer WorkshopNational Heart, Lung, And Blood Institute2010
  • Clinical Investigation Of Epigenetic TherapyNational Cancer Institute2006–2010
  • Clinical Trial OfficeNational Cancer Institute2005–2009
  • Hu1d10 In CLL: Clinical And Laboratory StudiesNational Cancer Institute2003–2006
  • Molecular Markers: Response To Chemo-Immunotherapy In C*National Cancer Institute2005
  • Epigenetic Targeted Therapy For Chronic Lymphocytic Leu*National Cancer Institute2005
  • Molecular Markers: Response To Chemo-Immunotherapy In CLNational Cancer Institute2004
  • Chronic Lymphocytic Leukemia:Epigenetic Targeted TherapyNational Cancer Institute2004
  • Depsipeptide: A Novel Histone Deacytlase Inhibitor In LNational Cancer Institute2002–2003
  • Clinical Investigation Of The Innate Immune SystemNational Cancer Institute2002
  • A Phase 1 Study Of Hud10 In Cll/Sll PatientsNational Cancer Institute2001–2002
  • Cancer And Leukemia Group BNational Cancer Institute1999

Professional Memberships

Hospital Affiliations

Dr. John Byrd, Dr. John Byrd, MD, Dr. J Byrd, Dr. John C. Byrd